富蘭克林坦伯頓全球投資系列-生技領航基金美元I(acc)股
64.66美元2.21(3.31%)
2024/12/12更新
績效 / 1月8.2%
3月4.27%
1年23.31%
晨星評等-
- 1.現金0.76%
- 2.股票12.20%
- 3.債券0.00%
- 4.其他87.04%
- 1.美國86.47%
- 2.歐元區4.47%
- 3.英國3.93%
- 4.歐洲不包含歐元區2.84%
- 5.加拿大0.89%
- 1.Vertex Pharmaceuticals Inc6.26%
- 2.Amgen Inc6.07%
- 3.Regeneron Pharmaceuticals Inc5.42%
- 4.Gilead Sciences Inc5.23%
- 5.Intra-Cellular Therapies Inc3.54%
- 6.argenx SE ADR3.25%
- 7.Jazz Pharmaceuticals PLC3.06%
- 8.Federal Home Loan Banks2.92%
- 9.AstraZeneca PLC ADR2.70%
- 10.Merus NV2.61%
- 1.現金0.76%
- 2.股票12.20%
- 3.債券0.00%
- 4.其他87.04%
- 1.美國86.47%
- 2.歐元區4.47%
- 3.英國3.93%
- 4.歐洲不包含歐元區2.84%
- 5.加拿大0.89%
- 1.Vertex Pharmaceuticals Inc6.26%
- 2.Amgen Inc6.07%
- 3.Regeneron Pharmaceuticals Inc5.42%
- 4.Gilead Sciences Inc5.23%
- 5.Intra-Cellular Therapies Inc3.54%
- 6.argenx SE ADR3.25%
- 7.Jazz Pharmaceuticals PLC3.06%
- 8.Federal Home Loan Banks2.92%
- 9.AstraZeneca PLC ADR2.70%
- 10.Merus NV2.61%